Journal articles: 'Maculopapular exanthema'

1

Fernández, Tahia D., Gabriela Canto, and Miguel Blanca. "Molecular mechanisms of maculopapular exanthema." Current Opinion in Infectious Diseases 22, no. 3 (June 2009): 272–78. http://dx.doi.org/10.1097/qco.0b013e3283298e62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pilar Hernández, Alfonso, Mahave Idoia González, Oribe Irene Vidal, del Pozo Gil Mª Dolores, Díaz Mónica Venturini, and Labairu Teófilo Lobera. "Maculopapular delayed exanthema due to ranitidine." Annals of Dermatological Research 4, no. 1 (December 23, 2020): 014–16. http://dx.doi.org/10.29328/journal.adr.1001012.

Full text

Abstract:

Ranitidine is a widely used drug in Europe and its intake is usually well tolerated. Hypersensitivity reactions due to ranitidine are uncommon. The immediate mild reactions type are the most prevalent. In some special cases a delayed type reaction such as contact dermatitis or severe reactions with systemic involvement have been reported. In the present paper, a case report of a 78-year old patient who experienced a maculopapular eruption after 7 days of oral treatment with ranitidine is described. Patch tests were performed twice with ranitidine with positive results confirming the diagnosis. In order to discard a double sensitization and a possible cross-reactivity phenomenon, patch test was performed once with famotidine, with a negative result. This is the first maculopapular exanthema reported as type IV hypersensitivity reaction to ranitidine confirmed by patch testing. Moreover, there are only two reported cases showing a double sensitization to ranitidine and to other H2-receptor antagonists by patch testing after a delayed reaction due to ranitidine, the other being H2-receptor antagonists involving cimetidine and nizatidine, not famotidine.

APA, Harvard, Vancouver, ISO, and other styles

3

Borja, J. M., P. A. Galindo, F. Feo, E. Gomez, and A. Lasanta. "Maculopapular exanthema from diacetyl-midecamycin (MOM)." Allergy 53, no. 10 (October 1998): 1004–5. http://dx.doi.org/10.1111/j.1398-9995.1998.tb03805.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Orsini, Marco, Jacqueline Fernandes Nascimento, Antônio Marcos da Silva Catharino, Marcos RG Freitas, and Acary Bullede Oliveira. "Exanthema after lamotrigine use: A clinical case." International Journal of Case Reports and Images 13, no. 1 (June 16, 2022): 20–23. http://dx.doi.org/10.5348/101314z01mo2022cr.

Full text

Abstract:

Introduction: Lamotrigine is a phenyltriazine compound that inhibits sodium and potassium channels in presynaptic neurons. Maculopapular exanthema is a common side effect of Lamotrigine therapy, occurring most frequently during the first eight weeks of treatment in approximately 3–10% of patients. Case Report: A 74-year-old female had started Lamotrigine 50 mg due to emotional lability and depression. About 8–9 weeks after the introduction of the drug she presented a rash with exanthema, maculopapular in appearance. The attending physician suggested discontinuation of the medication and reevaluation. Complete regression of the clinical picture occurred. No severe skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis were observed. Conclusion: Lamotrigine is effective for a variety of types of conditions involving neuronal excitability, however, such drug exposes the individual to side reactions ranging from mild skin rashes to even those leading to hospitalization. Measures such as adherence to the manufacturer’s dosing guidelines, titration, and intrinsic characteristics of the individual can minimize this effect.

APA, Harvard, Vancouver, ISO, and other styles

5

Koch, André, Georgi Tchernev, and Uwe Wollina. "Allergic Maculo-Papular Exanthema Due To Terbinafine." Open Access Macedonian Journal of Medical Sciences 5, no. 4 (July 20, 2017): 535–36. http://dx.doi.org/10.3889/oamjms.2017.105.

Full text

Abstract:

We report on a 76-year-old male patient who developed a maculopapular generalised exanthema due to terbinafine. Prick test was negative; patch test revealed a positive reaction after 48 h confirming the delayed-type allergic reaction. Non-pustular exanthema has only rarely been reported for terbinafine.

APA, Harvard, Vancouver, ISO, and other styles

6

Bircher, A. J., and M. Rutishauser. "Oral "desensitization" of maculopapular exanthema from ciprofloxacin." Allergy 52, no. 12 (December 1997): 1246–48. http://dx.doi.org/10.1111/j.1398-9995.1997.tb02534.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Fatkullina, G. R., V. A. Anokhin, and G. R. Khasanova. "Ring-shaped erythema and herpetic infections in children." Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) 66, no. 5 (December 9, 2021): 207–12. http://dx.doi.org/10.21508/1027-4065-2021-66-5-207-212.

Full text

Abstract:

Exanthema in children accompanies various diseases. Often, polymorphic elements on the skin occur against the background of infectious diseases. Until the second part of the XXth century, children’s classical infectology described only 6 diseases in children characterized by spotty and maculopapular rash. Now there are more than two dozen exanthemes in children with an “infectious origin”. The article considers 2 clinical cases of a relatively rare annular erythema in patients of 1 year 2 months and 11 months associated with chronic herpetic infections. The article presents photo documents of the dynamics of the skin process and laboratory parameters against the background of antiviral therapy.

APA, Harvard, Vancouver, ISO, and other styles

8

Eber, Elena, Teresa Deinlein, Birger Kränke, and Birgit Sadoghi. "Persisting maculopapular exanthema in a 78‐year‐old woman." JDDG: Journal der Deutschen Dermatologischen Gesellschaft 19, no. 5 (January 25, 2021): 786–89. http://dx.doi.org/10.1111/ddg.14375.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

FERNANDEZ, T., M. TORRES, C. ANTUNEZ, J. CORNEJOGARCIA, M. DELPRADO, G. REQUENA, M. BLANCA, and C. MAYORGA. "Role of Effector Cells In Drug-induced Maculopapular Exanthema." Journal of Allergy and Clinical Immunology 121, no. 2 (February 2008): S68. http://dx.doi.org/10.1016/j.jaci.2007.12.270.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Skowron, F., B. Bensaid, B. Balme, L. Depaepe, J. Kanitakis, A. Nosbaum, D. Maucort-Boulch, et al. "Comparative histological analysis of drug-induced maculopapular exanthema and DRESS." Journal of the European Academy of Dermatology and Venereology 30, no. 12 (July 16, 2016): 2085–90. http://dx.doi.org/10.1111/jdv.13832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Tirri, R., and D. Capocotta. "Incidental papillary thyroid cancer diagnosis in patient with adult-onset Still’s disease-like manifestations." Reumatismo 71, no. 1 (April 1, 2019): 42–45. http://dx.doi.org/10.4081/reumatismo.2019.1118.

Full text

Abstract:

Adult onset Still’s disease (AOSD) is a systemic inflammatory disease characterized primarily by a triad consisting of daily fever, arthritis and maculopapular exanthema. The pathogenesis and etiology of AOSD are unknown and the diagnosis, which can be very challenging, is often made by exclusion. Here, we report a case of a 61-year-old woman with a history of mild psoriatic arthritis, fever, arthritis and maculopapular exanthema. Her initial laboratory tests showed neutrophilic leukocytosis, hypertransaminasemia, and markedly elevated levels of the erythrocyte sedimentation rate and C-reactive protein. With a presumptive diagnosis of AOSD, based on Yamaguchi criteria, the patient started an extensive diagnostic work-up to exclude other potential differential diagnoses. With fluorodeoxyglucose (FDG) positron-emission tomography, a thyroid nodule with moderate FDG uptakes was detected. The fine needle aspiration biopsy led to diagnosis of papillary thyroid cancer. The history of psoriatic arthritis, the patient’s age, and atypical features of the skin rash described as not concomitant with fever flares, suggested a diagnosis of paraneoplastic AOSD-like manifestations.

APA, Harvard, Vancouver, ISO, and other styles

12

Afonso, Anaísa, Joana Cachão, Vitor Laerte Pinto Junior, and Teresa Gouveia. "Gianotti-Crosti syndrome: a challenging exanthema." BMJ Case Reports 14, no. 4 (April 2021): e240747. http://dx.doi.org/10.1136/bcr-2020-240747.

Full text

Abstract:

Gianotti-Crosti syndrome (GCS) is a self-limited condition, mainly affecting children younger than 6 years, less common in adolescents and adults. It consists of a viral exanthema with papular lesions with a flat top and symmetrical distribution, affecting predominantly extremities, gluteal region and extensor surfaces. It is often associated with viral infections but can also be related to bacterial infections, vaccination or be idiopathic. In this report, we present a case of GCS in a 13-year-old healthy female adolescent who presented with fever, odynophagia, prostration and diffuse maculopapular rash. The diagnosis of infectious mononucleosis due to infection by the Epstein-Barr virus was established. On the second week of the disease, a clinical recrudescence occurred, with worsening of the fever and modification of the exanthema characteristics. GCS is often an underdiagnosed entity. The differential diagnosis of viral exanthema can prove to be challenging and clinical suspicion is essential to achieve the diagnosis.

APA, Harvard, Vancouver, ISO, and other styles

13

Vorzheva, I. I., B. A. Chernyak, I. I. Vorzheva, and B. A. Chernyak. "CASE OF A DRESS SYNDROME WITH EOSINOPHILIC PNEUMONIA." Russian Journal of Allergy 8, no. 5 (October 15, 2011): 51–53. http://dx.doi.org/10.36691/rja808.

Full text

Abstract:

The case of the DRESS syndrome developed at the 64 years old patient after carbamazepine intake is reported. Clinical manifestation of a DRESS syndrome was characterized by a fever, leucocytosis, high eosinophilia of peripheral blood and sputum, multivisceral involving: skin (maculopapular exanthema), liver (hepatitis), lungs (eosinophilic pneumonia), lymphadenopathy. Treatment with prednisolone for two months (a starting doze of 60 mg /day) caused full recovery of the patient.

APA, Harvard, Vancouver, ISO, and other styles

14

Tapia, B., E. Morel, M. Á. Martín-Díaz, R. Díaz, J. Alves-Ferreira, P. Rubio, A. Padial, and T. Bellón. "Up-regulation of CCL17, CCL22 and CCR4 in drug-induced maculopapular exanthema." Clinical & Experimental Allergy 37, no. 5 (May 2007): 704–13. http://dx.doi.org/10.1111/j.1365-2222.2007.02699.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Li, Li-Juan, Fa-Yun Hu, Xin-Tong Wu, Dong-Mei An, Bo Yan, and Dong Zhou. "Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese." Epilepsy Research 106, no. 1-2 (September 2013): 296–300. http://dx.doi.org/10.1016/j.eplepsyres.2013.05.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Carvalho, Joana, and Georgeta Oliveira. "Systemic reaction during intradermal skin tests with beta-lactams." BMJ Case Reports 14, no. 3 (March 2021): e240050. http://dx.doi.org/10.1136/bcr-2020-240050.

Full text

Abstract:

Beta-lactam (BL) antibiotics are the most frequent cause of drug hypersensitivity in children, inducing both immediate and non-immediate reactions. Here we report a case of a 4-year-old child with a disseminated maculopapular exanthema 7 days after the first dose of amoxicillin–clavulanate, referred to our paediatric allergy department. Skin prick tests were negative. Intradermal tests were performed and, after 10 hours, indurated wheals larger than 10×10 mm with progressive erythema and disseminated maculopapular eruption were developed, related to amoxicillin and amoxicillin–clavulanate. Systemic reactions to BL skin tests are rarely reported and the majority are immediate reactions. This case illustrates a rare example of a non-immediate systemic reaction to intradermal tests, underlying the importance of skin testing before drug provocation tests in cases of moderate to severe non-immediate reactions.

APA, Harvard, Vancouver, ISO, and other styles

17

Oliveira, Raquel, Margarida Gonçalo, Carlos Faria, David Donaire, Benilde Barbosa, José Carlos Cardoso, Maria José Julião, José Moura, and Armando Carvalho. "A A Case of Flexural Exanthema as a Presenting Sign for COVID-19." Journal of the Portuguese Society of Dermatology and Venereology 78, no. 3 (September 27, 2020): 273–76. http://dx.doi.org/10.29021/spdv.78.3.1248.

Full text

Abstract:

We report a case of a 84-year-old male hospitalized for bacterial pneumonia who, during hospitalization, developed a flexural exanthema in parallel with a positive swab for SARS-CoV-2. Supportive therapy was instituted, the rash disappeared in 7 days and the patient fully recovered. At the same time, two other cases of SARS-CoV-2 infection occurred in the same ward. Histopathology and immunohistochemistry of a skin biopsy showed a scarce predominantly perivascular lymphocytic infiltration in the upper dermis, predominantly by CD4+ T cells, a slight epidermotropism, spongiosis and focal parakeratosis, compatible with a viral exanthema or a maculopapular drug eruption. Patch testing with possible culprit drugs were negative. We seek to add value in understanding all the manifestations of SARS-CoV-2 infection and to draw attention to the importance of early identification of skin manifestations in association with COVID-19.

APA, Harvard, Vancouver, ISO, and other styles

18

McCormack, Mark, Hongsheng Gui, Andrés Ingason, Doug Speed, Galen E. B. Wright, Eunice J. Zhang, Rodrigo Secolin, et al. "Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients." Neurology 90, no. 4 (December 29, 2017): e332-e341. http://dx.doi.org/10.1212/wnl.0000000000004853.

Full text

Abstract:

ObjectiveTo characterize, among European and Han Chinese populations, the genetic predictors of maculopapular exanthema (MPE), a cutaneous adverse drug reaction common to antiepileptic drugs.MethodsWe conducted a case-control genome-wide association study of autosomal genotypes, including Class I and II human leukocyte antigen (HLA) alleles, in 323 cases and 1,321 drug-tolerant controls from epilepsy cohorts of northern European and Han Chinese descent. Results from each cohort were meta-analyzed.ResultsWe report an association between a rare variant in the complement factor H–related 4 (CFHR4) gene and phenytoin-induced MPE in Europeans (p = 4.5 × 10–11; odds ratio [95% confidence interval] 7 [3.2–16]). This variant is in complete linkage disequilibrium with a missense variant (N1050Y) in the complement factor H (CFH) gene. In addition, our results reinforce the association between HLA-A*31:01 and carbamazepine hypersensitivity. We did not identify significant genetic associations with MPE among Han Chinese patients.ConclusionsThe identification of genetic predictors of MPE in CFHR4 and CFH, members of the complement factor H–related protein family, suggest a new link between regulation of the complement system alternative pathway and phenytoin-induced hypersensitivity in European-ancestral patients.

APA, Harvard, Vancouver, ISO, and other styles

19

Glossmann, Jan-Peter, Jan Oliver Staak, Claudia Wickenhauser, Volker Diehl, and Andreas Josting. "Extramedullar Acute Myeloid Leukemia (Granulocytic Sarcoma) with Arm Paresis, Maculopapular Exanthema and Organ Involvement." Leukemia & Lymphoma 44, no. 9 (January 2003): 1619–21. http://dx.doi.org/10.3109/10428190309178788.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

García-Gutiérrez, I., M. Acevedo, P. Tornero, A. Matilla, L. Márquez, A. Sánchez-Herrero, and A. Prieto-García. "Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen." Journal of Investigational Allergology and Clinical Immunology 29, no. 4 (April 2, 2019): 300–302. http://dx.doi.org/10.18176/jiaci.0377.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Fernández, T. D., C. Mayorga, J. A. Cornejo-García, M. J. Torres, C. Rondon, R. R-Pena, S. López, E. Martín, and M. Blanca. "Cytokine and Chemokine Expression in the Skin from Patients with Maculopapular Exanthema to Drugs." Journal of Allergy and Clinical Immunology 119, no. 1 (January 2007): S271. http://dx.doi.org/10.1016/j.jaci.2006.12.431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Fernandez‐Santamaría, Ruben, Francisca Palomares, Maria Salas, Inmaculada Doña, Gador Bogas, Adriana Ariza, Alba Rodriguez‐Nogales, et al. "Expression of the Tim3‐galectin‐9 axis is altered in drug‐induced maculopapular exanthema." Allergy 74, no. 9 (May 31, 2019): 1769–79. http://dx.doi.org/10.1111/all.13847.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Fernandez, T. D., C. Mayorga, M. J. Torres, J. A. Cornejo-Garcia, S. López, P. Chaves, C. Rondon, and M. Blanca. "Cytokine and chemokine expression in the skin from patients with maculopapular exanthema to drugs." Allergy 63, no. 6 (June 2008): 712–19. http://dx.doi.org/10.1111/j.1398-9995.2007.01607.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Glossmann, Jan-Peter, Jan Oliver Staak, Claudia Wickenhauser, Volker Diehl, and Andreas Josting. "Extramedullary Acute Myeloid Leukemia (Granulocytic Sarcoma) with Arm Paresis, Maculopapular Exanthema and Organ Involvement." Leukemia & Lymphoma 44, no. 9 (January 1, 2003): 1619–21. http://dx.doi.org/10.1080/1042819031000097410.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mitamura, Y., D. Schulz, I. Kolm, S. Oro, M. Levesque, E. Maverakis, C. Akdis, and M. Brüggen. "011 Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients?" Journal of Investigative Dermatology 141, no. 5 (May 2021): S2. http://dx.doi.org/10.1016/j.jid.2021.02.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Fernandez, T. D., M. J. Torres, S. Lopez, C. Antunez, E. Gomez, M. F. Del Prado, G. Canto, M. Blanca, and C. Mayorga. "Role of Effector Cells (CCR7−CD27−) and Effector-Memory Cells (CCR7−CD27+) in Drug-Induced Maculopapular Exanthema." International Journal of Immunopathology and Pharmacology 23, no. 2 (April 2010): 437–47. http://dx.doi.org/10.1177/039463201002300206.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Sukasem, Chonlaphat, Chonlawat Chaichan, Thapanat Nakkrut, Patompong Satapornpong, Kanoot Jaruthamsophon, Thawinee Jantararoungtong, Napatrupron Koomdee, et al. "Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients." Journal of Immunology Research 2018 (2018): 1–11. http://dx.doi.org/10.1155/2018/2780272.

Full text

Abstract:

The HLA-B∗15:02 allele has been reported to have a strong association with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in Thai patients. The HLA-B alleles associated with carbamazepine-induced maculopapular exanthema (MPE) and the drug reaction with eosinophilia and systemic symptoms (DRESS) among the Thai population have never been reported. The aim of the present study was to carry out an analysis of the involvement of HLA-B alleles in carbamazepine-induced cutaneous adverse drug reactions (cADRs) in the Thai population. A case-control study was performed by genotyping the HLA-B alleles of Thai carbamazepine-induced hypersensitivity reaction patients (17 MPE, 16 SJS/TEN, and 5 DRESS) and 271 carbamazepine-tolerant controls. We also recruited 470 healthy Thai candidate subjects who had not taken carbamazepine. HLA-B∗15:02 showed a significant association with carbamazepine-induced MPE (P=0.0022, odds ratio (OR) (95% confidence interval [CI]) = 7.27 (2.04–25.97)) and carbamazepine-induced SJS/TEN (P=4.46×10−13; OR (95% CI) = 70.91(19.67–255.65)) when compared with carbamazepine-tolerant controls. Carbamazepine-induced SJS/TEN also showed an association with HLA-B∗15:21 allele (P=0.013; OR (95% CI) = 9.54 (1.61–56.57)) when compared with carbamazepine-tolerant controls. HLA-B∗58:01 allele was significantly related to carbamazepine-induced MPE (P=0.007; OR (95% CI) = 4.73 (1.53–14.66)) and DRESS (P=0.0315; OR (95% CI) = 7.55 (1.20–47.58)) when compared with carbamazepine-tolerant controls. These alleles may serve as markers to predict carbamazepine-induced cADRs in the Thai population.

APA, Harvard, Vancouver, ISO, and other styles

28

Kremić, Zorana, Željko P. Mijušković, and Lidija Kandolf-Sekulović. "Dress Syndrome - A Case Report." Serbian Journal of Dermatology and Venereology 8, no. 2 (June 1, 2016): 95–100. http://dx.doi.org/10.1515/sjdv-2016-0009.

Full text

Abstract:

Abstract The drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is an adverse drug-induced reaction that occurs most commonly after exposure to drugs, most frequently anticonvulsants, sulfa derivates, antidepressants, nonsteroidal anti-inflammatory drugs, and antimicrobials. We present a 61-year-old male, with a generalized maculopapular exanthema on the trunk, face, extremities, palms, soles, palate, and fever (38°C). His medical history was notable for generalized epilepsy, treated with carbamazepine during 1 month. The diagnosis of DRESS syndrome was confirmed by specific RegiSCAR criteria. In our case, skin eruptions were successfully treated with oral methylprednisolone, cephalexin, and topical corticosteroid ointment. In conclusion, although the mechanisms of this syndrome are not completely understood, numerous cases were reported in children and adults. This syndrome should be considered in every patient with skin eruption, fever, eosinophilia, liver and hematological abnormalities. Prompt recognition, supportive therapy and initiation of corticosteroids may prevent systemic manifestations.

APA, Harvard, Vancouver, ISO, and other styles

29

Pinheiro, Talys J., Luis F. Guimarães, Marcus Tulius T. Silva, and Cristiane N. Soares. "Neurological manifestations of Chikungunya and Zika infections." Arquivos de Neuro-Psiquiatria 74, no. 11 (November 2016): 937–43. http://dx.doi.org/10.1590/0004-282x20160138.

Full text

Abstract:

ABSTRACT The epidemics of Chikungunya virus (CHIKV) and Zika virus (ZIKV) infections have been considered the most important epidemiological occurrences in the Americas. The clinical picture of CHIKV infection is characterized by high fever, exanthema, myalgia, headaches, and arthralgia. Besides the typical clinical picture of CHIKV, atypical manifestations of neurological complications have been reported: meningo-encephalitis, meningoencephalo-myeloradiculitis, myeloradiculitis, myelitis, myeloneuropathy, Guillain-Barré syndrome and others. The diagnosis is based on clinical, epidemiological, and laboratory criteria. The most common symptoms of ZIKV infection are skin rash (mostly maculopapular), fever, arthralgia, myalgia, headache, and conjunctivitis. Some epidemics that have recently occurred in French Polynesia and Brazil, reported the most severe conditions, with involvement of the nervous system (Guillain-Barré syndrome, transverse myelitis, microcephaly and meningitis). The treatment for ZIKV and CHIKV infections are symptomatic and the management for neurological complications depends on the type of affliction. Intravenous immunoglobulin, plasmapheresis, and corticosteroid pulse therapy are options.

APA, Harvard, Vancouver, ISO, and other styles

30

Kloypan, Chiraphat, Napatrupron Koomdee, Patompong Satapornpong, Therdpong Tempark, Mohitosh Biswas, and Chonlaphat Sukasem. "A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine." Pharmaceuticals 14, no. 11 (October 25, 2021): 1077. http://dx.doi.org/10.3390/ph14111077.

Full text

Abstract:

Human leukocyte antigen (HLA) encoded by the HLA gene is an important modulator for immune responses and drug hypersensitivity reactions as well. Genetic polymorphisms of HLA vary widely at population level and are responsible for developing severe cutaneous adverse drug reactions (SCARs) such as Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), maculopapular exanthema (MPE). The associations of different HLA alleles with the risk of drug induced SJS/TEN, DRESS and MPE are strongly supportive for clinical considerations. Prescribing guidelines generated by different national and international working groups for translation of HLA pharmacogenetics into clinical practice are underway and functional in many countries, including Thailand. Cutting edge genomic technologies may accelerate wider adoption of HLA screening in routine clinical settings. There are great opportunities and several challenges as well for effective implementation of HLA genotyping globally in routine clinical practice for the prevention of drug induced SCARs substantially, enforcing precision medicine initiatives.

APA, Harvard, Vancouver, ISO, and other styles

31

van Seggelen, Wouter O., Filip Y. De Vos, Heike Röckmann, Marijke R. van Dijk, and Joost J. C. Verhoeff. "Occurrence of an Abscopal Radiation Recall Phenomenon in a Glioblastoma Patient Treated with Nivolumab and Re-Irradiation." Case Reports in Oncology 12, no. 3 (November 27, 2019): 896–900. http://dx.doi.org/10.1159/000504698.

Full text

Abstract:

Glioblastoma multiforme is the most frequent primary brain tumor. The clinical course of glioblastoma is almost invariably fatal. Combined chemo-irradiation with temozolomide is currently the standard of care for newly diagnosed glioblastoma and concurrent Nivolumab, an anti-PD-1 monoclonal antibody is being studied for de novo glioblastoma. We present a 62-year old patient with glioblastoma, which was discovered during evaluation of sudden-onset moderate ataxia. Following craniotomy of the glial tumour he received chemo radiation. During this first-line treatment the patient participated in the CA209–548 phase III placebo controlled study investigating the addition of concurrent nivolumab. One month after the last administration of nivolumab after 60 weeks of study participation, magnetic resonance imaging scan showed progressive disease. Therefore stereotactic re-irradiation was given. Five days after completing radiation therapy and 50 days after his last nivolumab course he developed a mild diffuse generalized pruritic maculopapular exanthema. Skin biopsy was very indicative for a drug hypersensitivity reaction. The maculopapular rash and pruritus was successfully treated with moderate potency topical corticosteroids and prednisone. With the introduction of PD1/PD-L1 inhibitors and other immunotherapies tweaking the immune system to target cancer cells one can argue that once local radiation triggers a local immune mediated hypersensitivity reaction as seen in radiation recall dermatitis, the subsequent hypersensitivity reaction which would traditionally only be a local reaction is now possible to advance to more pronounced (systemic) reactions as seen in an abscopal effect. Therefore, we propose a combined name to coin this effect, the abscopal radiation recall phenomenon.

APA, Harvard, Vancouver, ISO, and other styles

32

Fernandez, Tahia D., Francisca Palomares, Maria Salas, Inmaculada Doña, Esther Barrionuevo, Adriana Ariza, Raquel Jurado, Miguel Blanca, Cristobalina Mayorga, and María José Torres. "The Low Expression of Tim-3 in Patients with Maculopapular Exanthema (EMP) Induced By Drugs Can Impaired Disease Control." Journal of Allergy and Clinical Immunology 137, no. 2 (February 2016): AB45. http://dx.doi.org/10.1016/j.jaci.2015.12.150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kepil Özdemir, Seçil, and Sevim Bavbek. "Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management." Allergy and Asthma Proceedings 41, no. 2 (March 1, 2020): e37-e44. http://dx.doi.org/10.2500/aap.2020.41.190033.

Full text

Abstract:

Background: Proton-pump inhibitors (PPI) are one of the most commonly prescribed drugs, and they are generally well tolerated. However, several immediate and delayed hypersensitivity reactions due to PPIs have been reported. Objective: To review the clinical characteristics and management of immune-mediated immediate and delayed hypersensitivity reactions to PPIs. Methods: We performed a search of a medical literature data base from January 1980 to October 2019 by using keywords that included “proton-pump inhibitors” and “hypersensitivity.” Results: Anaphylaxis is the most-common clinical presentation in patients with immediate hypersensitivity reactions to PPIs, followed by urticaria and/or angioedema. Occupational contact dermatitis, maculopapular eruption, fixed drug eruption, symmetrical drug-related intertriginous and flexural exanthema, and severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis have also been reported with PPIs. Conclusion: The current knowledge and severity of the reported reactions indicated the importance of consideration of a causal relationship between hypersensitivity reactions and PPIs, and awareness of the existence of cross-reactivity among PPIs.

APA, Harvard, Vancouver, ISO, and other styles

34

Chen, Chun-Bing, Riichiro Abe, Ren-You Pan, Chuang-Wei Wang, Shuen-Iu Hung, Yi-Giien Tsai, and Wen-Hung Chung. "An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity." Journal of Immunology Research 2018 (2018): 1–22. http://dx.doi.org/10.1155/2018/6431694.

Full text

Abstract:

Drug hypersensitivity may manifest ranging from milder skin reactions (e.g., maculopapular exanthema and urticaria) to severe systemic reactions, such as anaphylaxis, drug reactions with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS), or Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). Current pharmacogenomic studies have made important strides in the prevention of some drug hypersensitivity through the identification of relevant genetic variants, particularly for genes encoding drug-metabolizing enzymes and human leukocyte antigens (HLAs). The associations identified by these studies are usually drug, phenotype, and ethnic specific. The drug presentation models that explain how small drug antigens might interact with HLA and T cell receptor (TCR) molecules in drug hypersensitivity include the hapten theory, the p-i concept, the altered peptide repertoire model, and the altered TCR repertoire model. The broad spectrum of clinical manifestations of drug hypersensitivity involving different drugs, as well as the various pathomechanisms involved, makes the diagnosis and management of it more challenging. This review highlights recent advances in our understanding of the predisposing factors, immune mechanisms, pathogenesis, diagnostic tools, and therapeutic approaches for drug hypersensitivity.

APA, Harvard, Vancouver, ISO, and other styles

35

Shi, Yi-Wu, Fu-Li Min, Dong Zhou, Bin Qin, Juan Wang, Fa-Yun Hu, Ying-Kit Cheung, et al. "HLA-A*24:02 as a common risk factor for antiepileptic drug–induced cutaneous adverse reactions." Neurology 88, no. 23 (May 5, 2017): 2183–91. http://dx.doi.org/10.1212/wnl.0000000000004008.

Full text

Abstract:

Objective:To investigate the involvement of human leukocyte antigen (HLA) loci in aromatic antiepileptic drug–induced cutaneous adverse reactions.Methods:A case-control study was performed to detect HLA loci involved in aromatic antiepileptic drug–induced Stevens-Johnson syndrome in a southern Han Chinese population. Between January 1, 2006, and December 31, 2015, 91 cases of Stevens-Johnson syndrome induced by aromatic antiepileptic drugs and 322 matched drug-tolerant controls were enrolled from 8 centers. Important genotypes were replicated in cases with maculopapular eruption and in the meta-analyses of data from other populations. Sequence-based typing determined the HLA-A, HLA-B, HLA-C, and HLA-DRB1 genotypes.Results:HLA-B*15:02 was confirmed as strongly associated with carbamazepine-induced Stevens-Johnson syndrome (p = 5.63 × 10−15). In addition, HLA-A*24:02 was associated significantly with Stevens-Johnson syndrome induced by the aromatic antiepileptic drugs as a group (p = 1.02 × 10−5) and by individual drugs (carbamazepine p = 0.015, lamotrigine p = 0.005, phenytoin p = 0.027). Logistic regression analysis revealed a multiplicative interaction between HLA-B*15:02 and HLA-A*24:02. Positivity for HLA-A*24:02 and/or HLA-B*15:02 showed a sensitivity of 72.5% and a specificity of 69.0%. The presence of HLA-A*24:02 in cases with maculopapular exanthema was also significantly higher than in controls (p = 0.023). Meta-analysis of data from Japan, Korea, Malaysia, Mexico, Norway, and China revealed a similar association.Conclusions:HLA-A*24:02 is a common genetic risk factor for cutaneous adverse reactions induced by aromatic antiepileptic drugs in the southern Han Chinese and possibly other ethnic populations. Pretreatment screening is recommended for people in southern China.

APA, Harvard, Vancouver, ISO, and other styles

36

Kuodza, G. E., and P. O. Kolesnyk. "AN ANTIBIOTIC DRUG-INDUCED ALLERGIC REACTION IN A PATIENT WITH MULTIPLE COMORBIDITIES. CLINICAL CASE." Здобутки клінічної і експериментальної медицини, no. 2 (August 20, 2020): 211–14. http://dx.doi.org/10.11603/1811-2471.2020.v.i2.11348.

Full text

Abstract:

Drug induced allergic reactions due to antibiotics rarely occur. Penicillin is the antibiotic class that is mostly commonly associated with drug induced allergic reactions (10 %). They are followed by quinolones (2 %) which will be discussed in this case based review. Fluoroquinolones allergic reactions can either present as an immediate reaction which requires urgent medical attention or a delayed reaction. Among the antibiotics of this class, moxifloxacin has been reported as the drug which is likely to result in occurrence of an allergic reaction. Some of the dermatologic eruptions that could manifest include maculopapular exanthema, urticarial, Steven Johnson Syndrome, fixed drug eruptions and drug rash with eosinophilia and systemic symptoms (DRESS). The diagnosis needs a thorough history and physical examination, skin test, in vitro testing and drug provocation tests. Management includes discontinuation of the provoking agent and administration of antihistamines or corticosteroids depending on the situation. The case of the 75 year old lady who had an allergic reaction following administrations of ciprofloxacin and follow up management plan is described in the article. The case illustrates and urgent necessity of quaternary prevention in primary care to avoid harming patients while choosing the best and safe therapy.

APA, Harvard, Vancouver, ISO, and other styles

37

Pinto Gouveia, M., A. Gameiro, I. Coutinho, N. Pereira, J. C. Cardoso, and M. Gonçalo. "Overlap between maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms among cutaneous adverse drug reactions in a dermatology ward." British Journal of Dermatology 175, no. 6 (September 6, 2016): 1274–83. http://dx.doi.org/10.1111/bjd.14704.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Balas, Antonio, Elena Ramírez, Elena Trigo, Rosario Cabañas, Ana Fiandor, Marta Arsuaga, Victoria Lerma, et al. "HLA-A∗68, -A∗11:01, and -A∗29:02 alleles are strongly associated with benznidazole-induced maculopapular exanthema (MPE)/DRESS." Journal of Allergy and Clinical Immunology: In Practice 8, no. 9 (October 2020): 3198–200. http://dx.doi.org/10.1016/j.jaip.2020.05.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Fernandez, Tahia D., Maria Francisca Palomares, Ruben Fernandez-Santamaria, Alba Rodriguez-Nogales, Maria Jose Rodriguez, Ana Molina Bueno, María Isabel Montañez, Jose Julio Laguna, M. J. Torres, and Cristobalina Mayorga. "Proliferation control of specific-effector T cells and T-Regulatory cells by Tim-3 and Galectin-9 in Drug-Induced Maculopapular Exanthema." Journal of Allergy and Clinical Immunology 143, no. 2 (February 2019): AB65. http://dx.doi.org/10.1016/j.jaci.2018.12.198.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

FAZULZYANOVA, A. I., S. V. TKACHEVA, and D. A. SADYKOVA. "Imported cases of dengue fever among residents of the Republic of Tatarstan." Practical medicine 20, no. 2 (2022): 73–77. http://dx.doi.org/10.32000/2072-1757-2022-2-73-77.

Full text

Abstract:

The article presents an analysis of clinical-epidemiological and laboratory-instrumental data of 15 patients with dengue fever (DF), residents of the Republic of Tatarstan, who visited regions endemic for DF as tourists. To verify the diagnosis, PCR diagnostics of blood serum for dengue virus RNA and determination of dengue virus serotypes were carried out. The classical form of the disease of moderate severity was diagnosed in 14 (93.3%) patients. The clinical picture was characterized by an acute onset, fever, chills, myalgia, arthralgia. The total duration of the febrile period varied from 3 to 7 (4.1 (2.09)) days. In 7 (46.7%) patients, maculopapular exanthema of various localization was observed, in 43% it was hemorrhagic in nature and was accompanied by itching (28.6%). In 5 (33.3%) cases, dyspeptic syndrome developed. 4 (26.7%) patients were diagnosed with respiratory syndrome. Hematological changes were characterized by thrombocytopenia in 93.3% (105.6 (35.9) 109/l) and leukopenia in 86.7% (3.2 (1.9) 109/l) of patients. 7 (46.7%) patients had a moderate cytolytic syndrome with a predominance of ALT (61 (43.3) U/l) and AST (59.6 (36.9) U/l) activity in the early period of the disease. In 7 (46.7%) patients, an increase in the pulmonary pattern of both lungs with perivascular and peribronchial changes was diagnosed radiographically. Sonographic examination of the abdominal organs revealed an increase in the size of the liver and spleen in 3 (20%) patients. Thus, imported cases of DF in the Republic of Tatarstan were characterized by the development of the classical moderate form caused by serotypes 1-3. Due to the increased DF incidence in the Russian Federation and, in particular, in the Republic of Tatarstan, it is necessary to improve medical alertness in diagnosing the disease characterized by fever combined with arthralgia, myalgia and exanthema in people who returned from endemic countries. Due to the lack of vaccination in the Russian Federation, it is necessary to inform patients who recovered from DF about the risk of developing a hemorrhagic form of the disease in case of re-infection.

APA, Harvard, Vancouver, ISO, and other styles

41

Nykytyuk, S. O., S. S. Levenets, and Z. Ya Borys. "Toxicoderma in a child as a complication after a bedbug bite." CHILD`S HEALTH 17, no. 4 (September 20, 2022): 199–203. http://dx.doi.org/10.22141/2224-0551.17.4.2022.1517.

Full text

Abstract:

Background. Toxic dermatitis is an adverse skin reaction caused by various factors. Analysis of clinical cases helps identify problems, and plan future studies, which can change the understanding of the consequences of the disease. The purpose was to improve the diagnosis of allergic dermatoses in children, to analyze clinical and paraclinical features of their course, and biomarkers of sensitization to allergens. Materials and methods. Presentation of a case study was a basis for discussion, as well as literature search in the MEDLINE and Scopus databases. The study was conducted in accordance with the principles of the Declaration of Helsinki. The research protocol was approved by the ethics committee of the institution mentioned in the work. Informed consent of child’s parents was obtained for the research. Results. The clinical picture of toxic dermatitis is very diverse, almost any type of lesion can occur, and often the clinical symptoms are very similar to skin diseases that are not caused by various toxic agents. The most common clinical symptom is maculopapular exanthema. Conclusions. The peculiarity of the presented case is toxicoderma in a child after a bedbug bite. It is important to establish the correct diagnosis of toxic dermatitis, identify toxic agent, stop its exposure and treat the adverse reaction, usually with antihistamines and corticosteroids.

APA, Harvard, Vancouver, ISO, and other styles

42

Kouotou, Emmanuel Armand, Jobert Richie Nansseu, Vanessa Nancy Ngono, Sandra A. Tatah, Anne Cecile Zoung-Kanyi Bissek, and Elie Claude Ndjitoyap Ndam. "Prevalence and Clinical Profile of Drug Eruptions among Antiretroviral Therapy-Exposed HIV Infected People in Yaoundé, Cameroon." Dermatology Research and Practice 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/6216193.

Full text

Abstract:

Background. Prevalence and incidence of drug eruptions vary around the world and are influenced by some key factors including HIV infection. Objective. This study aimed to find the peculiarities of drug eruptions in people living with HIV (PLHIV) and on antiretroviral therapy (ART). Methods. This was a retrospective cross-sectional study including ART-taking PLHIV, aged 15+ years, followed up between January 2010 and December 2014 at the day-care unit of the Yaoundé Central Hospital, and who presented with drug eruptions after ART initiation. Results. Of 6,829 ART-experiencing PLHIV, 41 presented with drug eruptions, giving a prevalence of 0.6%. The M/F sex ratio equaled 0.17. The mean age was 41.07 ± 11.36 years. Benign drug eruptions accounted for 83.3%. Milder forms were essentially maculopapular exanthema (36.6%), fixed pigmented erythema (7.3%), and urticaria (4.9%). Severe forms were represented by multiform erythema (4.9%), toxic epidermal necrolysis (2.4%), and drug hypersensitivity syndrome (2.4%). The Zidovudine + Lamivudine + Efavirenz ART-protocol was received by 48.8% of patients and 69% of patients were receiving Cotrimoxazole prophylaxis. Nevirapine, Efavirenz, Zidovudine, and Cotrimoxazole were suspected as the potential causes in 43.7%, 4.8%, 2.4%, and 26.8% of cases, respectively. Conclusion. Drug eruptions seem infrequent among ART-exposed HIV infected adult Cameroonians.

APA, Harvard, Vancouver, ISO, and other styles

43

Chu, Mu-Tzu, Wan-Chun Chang, Shih-Cheng Pao, and Shuen-Iu Hung. "Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators." Biomedicines 11, no. 1 (January 10, 2023): 177. http://dx.doi.org/10.3390/biomedicines11010177.

Full text

Abstract:

Drug hypersensitivity reactions are classified into immediate and delayed types, according to the onset time. In contrast to the immediate type, delayed drug hypersensitivity mainly involves T lymphocyte recognition of the drug antigens and cell activation. The clinical presentations of such hypersensitivity are various and range from mild reactions (e.g., maculopapular exanthema (MPE) and fixed drug eruption (FDE)), to drug-induced liver injury (DILI) and severe cutaneous adverse reactions (SCARs) (e.g., Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP)). The common culprits of delayed drug hypersensitivity include anti-epileptics, antibiotics, anti-gout agents, anti-viral drugs, etc. Delayed drug hypersensitivity is proposed to be initiated by different models of molecular recognition, composed of drug/metabolite antigen and endogenous peptide, HLA presentation, and T cell receptor (TCR) interaction. Increasing the genetic variants of HLA loci and drug metabolic enzymes has been identified to be responsible for delayed drug hypersensitivity. Furthermore, preferential TCR clonotypes, and the activation of cytotoxic proteins/cytokines/chemokines, are also involved in the pathogenesis of delayed drug hypersensitivity. This review provides a summary of the current understanding of the molecular recognition, genetic susceptibility, and immune mediators of delayed drug hypersensitivity.

APA, Harvard, Vancouver, ISO, and other styles

44

Skiljevic, Dusan, Milica Colovic, Dragana Bogatic, Svetlana Popadic, and Ljiljana Medenica. "Granulomatous rosacea: Like leukemid in a patient with acute myeloid leukemia." Vojnosanitetski pregled 65, no. 7 (2008): 565–68. http://dx.doi.org/10.2298/vsp0807565s.

Full text

Abstract:

Introduction. Skin findings in leukemias may be divided into specific lesions (leukemia cutis) and non-specific lesions (leukemids) which may be found in up to 80% of all patients with leukemias. The leukemids vary clinically and they are usually a manifestation of bone marrow or immunologic impairment, but also Sweet syndrome, pyoderma gangrenosum, erythroderma, maculopapular exanthema, prurigo-like papules, generalized pigmentation, follicular mucinosis, generalized pruritus may be found during the course of leukemia. Case report. We report a 70-year-old male with a 3-month history of erythema, papules and pustules on the face, ears and neck and over a month history of refractory anemia, anorexia, weight loss, malaise, and fever. Physical examination revealed symmetric erythematous, violaceous papules, papulo-nodules and plaques with slate scale and sparse, small pustules on the face, earlobes and neck. Histopathologic findings of involved skin showed diffuse mixed inflammatory cell infiltrate with perifollicular accentuation and focal granulomatous inflammation in the papillary and upper reticular dermis. Extensive checkup revealed the presence of acute myeloid leukemia French- American-British (FAB) classification subtype M2, with signs of three-lineage dysplasia. The patient was treated by L6 protocol which led to complete remission, both in bone marrow and skin, but after seven months he had relapse of leukemia with the fatal outcome. Conclusion. This case indicates the importance of skin eruptions in the context of hematological malignancies.

APA, Harvard, Vancouver, ISO, and other styles

45

Atzori, Laura, Anna Luisa Pinna, Monica Pau, Natalia Aste, Myriam Zucca, and Caterina Ferreli. "Adverse Cutaneous Reactions to Selective Cyclooxygenase 2 Inhibitors: Experience of an Italian Drug-Surveillance Center." Journal of Cutaneous Medicine and Surgery 10, no. 1 (January 2006): 31–35. http://dx.doi.org/10.1007/7140.2006.00012.

Full text

Abstract:

Background: Selective cyclooxygenase (COX) 2 nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with a general lower incidence of side effects compared with nonselective NSAIDs. Postmarketing information has highlighted the need to reassess the risk evaluation for specific organs, including the skin. Objective: A prospective databank to record all cases of adverse cutaneous reactions associated with the use of COX inhibitors was conducted at the Centre for Drug Surveillance of the Dermatology Department of Cagliari University. Material and Methods: An intensive surveillance program from November 2000 to October 2004, adopting the World Health Organization Collaborating Centre for Drug Monitoring causality assessment criteria and algorithm. Results: Seventeen cases, 4 male and 13 female, were studied. None had previously presented any drug intolerance or allergy. Clinical manifestations were mainly maculopapular exanthema followed by urticaria-angioedema. A severe case of leukocytoclastic vasculitis was also observed. Responsible drugs were celecoxib (13 cases; 76%), rofecoxib (3 cases; 18%), and etoricoxib (1 case; 6%). All cases recovered with drug withdrawal. Causality was probable for all eruptions, except for the fixed drug eruption, for which causality was certain. Discussion: Although most cases were associated with celecoxib, the observation of severe eruptions owing to rofecoxib and etoricoxib in this prospective study is consistent with a class effect of COX inhibitors on the skin, which merits further studies to explain the fine underlying mechanisms.

APA, Harvard, Vancouver, ISO, and other styles

46

Fricke-Galindo, Ingrid, Iris E. Martínez-Juárez, Nancy Monroy-Jaramillo, Helgi Jung-Cook, Ramcés Falfán-Valencia, Alberto Ortega-Vázquez, María Elisa Alonso-Vilatela, and Marisol López-López. "HLA-A*02:01:01/-B*35:01:01/-C*04:01:01 haplotype associated with lamotrigine-induced maculopapular exanthema in Mexican Mestizo patients." Pharmacogenomics 15, no. 15 (November 2014): 1881–91. http://dx.doi.org/10.2217/pgs.14.135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ye, Y. ‐M, G. ‐Y Hur, S. ‐H Kim, G. ‐Y Ban, Y. ‐K Jee, D. J. Naisbitt, H. ‐S Park, and S. ‐H Kim. "Drug‐specific CD4 + T‐cell immune responses are responsible for antituberculosis drug‐induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome." British Journal of Dermatology 176, no. 2 (December 22, 2016): 378–86. http://dx.doi.org/10.1111/bjd.14839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Doshi, BhavanaR, and BS Manjunathswamy. "Maculopapular drug eruption versus maculopapular viral exanthem." Indian Journal of Drugs in Dermatology 3, no. 1 (2017): 45. http://dx.doi.org/10.4103/ijdd.ijdd_19_17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lavrentieva, I. N., A. Yu Antipova, M. A. Bichurina, I. V. Khamitova, O. N. Nikishov, and A. A. Kuzin. "Parvirus infection markers in persons with exantemic diseases and in risk groups." Journal Infectology 11, no. 3 (October 9, 2019): 110–17. http://dx.doi.org/10.22625/2072-6732-2019-11-3-110-117.

Full text

Abstract:

Background. In the Russian Federation the number of a parvovirus В19 infection cases has increased significantly with the introduction of rubella into the measles elimination program and laboratory examination of patients with maculopapular rash and fever. The aim of study was the examination of the distribution of the parvovirus В19 infection in the North-Western Federal District. Materials and methods. In 2014–2017, 1044 blood sera of patients with exanthema diseases from different territories of the North-Western Federal District have been investigated with «Anti-Parvovirus B19 ELISA IgM» kit (EUROIMMUN, Germany) to detect IgM antibody, and 733 blood sera of clinically healthy men and women 18 to 60 years old have been tested for IgG antibodies using the «Anti-Parvovirus B19 ELISA IgG» kit (EUROIMMUN, Germany). Results. Parvovirus В19 infection is contentiously detected in 10 of the 11 territories of the district. Typical is the winterspring seasonality; in terms of the age structure – prevalence of children 3–6 (25,3% of cases) and 7–14 (33,3% of cases) years old was detected. A high proportion of seropositivity was established among the examined donors from the higher educational institutions of Saint Petersburg (75,4–88,9%%). Low rate of seropositivity (56,7%) was detected among pregnant women. A high proportion of false negative results in the primary diagnosis of parvovirus infection has been revealed. Conclusion. Parvovirus В19 infection is widespread in the territories of the North-Western of the Russia, mainly among children. The results indicate the feasibility of conducting a laboratory examination of pregnant women who are contact for exanthemous diseases, for markers of parvovirus infection; on the importance of screening donor blood for PV B19 DNA with “culling” pools characterized by high viral load; on the need for differential laboratory diagnosis between rubella and parvovirus infection.

APA, Harvard, Vancouver, ISO, and other styles

50

Kudelka, A. P., D. Tresukosol, C. L. Edwards, R. S. Freedman, C. Levenback, P. Chantarawiroj, C. Gonzalez de Leon, et al. "Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma." Journal of Clinical Oncology 14, no. 5 (May 1996): 1552–57. http://dx.doi.org/10.1200/jco.1996.14.5.1552.

Full text

Abstract:

PURPOSE To determine the efficacy and toxicity of topotecan administered as a 5-day intravenous infusion in patients with advanced ovarian cancer refractory to cisplatin-based chemotherapy. PATIENTS AND METHODS Thirty patients with advanced epithelial ovarian cancer refractory to cisplatin-based chemotherapy received intravenous infusions of topotecan 1.5 mg/m2 delivered over 30 minutes each day for 5 days. A course was repeated every 21 days. The patient eligibility requirements included age > or = 18 years, Zubrod score < or = 2, measurable disease, adequate hepatic and renal function, neutrophil count > or = 1,500/microL, platelet count > or = 100,000/microL, and anticipated survival > or = 3 months. RESULTS Twenty eight patients were assessable for response and toxicity. All patients were assessable for survival. The major toxicity from administration of topotecan at this dose schedule was myelosuppression; 21 patients required dose reductions. Four patients had neutropenic fever that required hospitalization, and seven patients required platelet transfusions. Maculopapular pruritic exanthema occurred in 20% of patients; gastrointestinal side effects were mild. No deaths were reported on the study. At dose levels of 1.5, 1.25, and 1.0 mg/m2, 61%, 31%, and 25% of patients, respectively, required dose reductions. Of 28 assessable patients, four (14%; 95% confidence interval [CI], 4% to 34%) achieved a partial response (PR) at a median of 1.4 months and lasting 8.9 months, and 17 had stable disease (SD). The overall median survival time was 10.0 months (95% CI, 8.1 to 13.5). CONCLUSION Topotecan shows modest clinical activity against cisplatin-refractory ovarian cancer, although the dose-intensity is compromised by the depth of the granulocyte nadir and the duration of granulocytopenia. Further studies of topotecan may necessitate a reevaluation of optimal dose schedule, with the possible incorporation of multilineage cytokines, and its activity in taxane-resistant tumors.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Maculopapular exanthema'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles